CORC

浏览/检索结果: 共30条,第1-10条 帮助

已选(0)清除 条数/页:   排序方式:
Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor 期刊论文
THORACIC CANCER, 2022
作者:  Wang, Wenxian;  Wang, Qian;  Xu, Chunwei;  Li, Ziming;  Song, Zhengbo
收藏  |  浏览/下载:32/0  |  提交时间:2022/12/23
Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China 期刊论文
THORACIC CANCER, 2022
作者:  Xu, Chunwei;  Si, Lu;  Wang, Wenxian;  Li, Ziming;  Song, Zhengbo
收藏  |  浏览/下载:36/0  |  提交时间:2022/12/22
Treatment outcomes and prognosis of patients with primary and acquired BRAF-mutated non-small cell lung cancer: A multicenter retrospective study 期刊论文
GENES CHROMOSOMES & CANCER, 2022
作者:  Wang, Wenxian;  Gu, Xiaodong;  Si, Jinfei;  Pu, Xingxiang;  Wang, Liping
收藏  |  浏览/下载:31/0  |  提交时间:2022/05/16
Benzenesulfonic acid-based hydrotropic system for achieving lignocellulose separation and utilization under mild conditions 期刊论文
BIORESOURCE TECHNOLOGY, 2021, 卷号: 337, 页码: 7
作者:  Dong, Maolin;  Wu, Chen;  Chen, Lidong;  Zhou, Xuelian;  Yang, Weisheng
收藏  |  浏览/下载:29/0  |  提交时间:2021/10/15
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 期刊论文
JOURNAL OF HEPATOLOGY, 2019, 卷号: 70
作者:  Gong, Guozhong;  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun
收藏  |  浏览/下载:57/0  |  提交时间:2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载:46/0  |  提交时间:2019/12/05
Genetic mechanisms of arsenic detoxification and metabolism in bacteria 期刊论文
CURRENT GENETICS, 2019, 卷号: 65, 期号: 2
作者:  Yan, Ge;  Chen, Xingxiang;  Du, Shiming;  Deng, Zixin;  Wang, Lianrong
收藏  |  浏览/下载:3/0  |  提交时间:2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载:36/0  |  提交时间:2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载:38/0  |  提交时间:2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载:32/0  |  提交时间:2019/12/05


©版权所有 ©2017 CSpace - Powered by CSpace